ClinicalTrials.gg
CompletedNCT06184568Updated Jun 11, 2026

A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity

A Phase 3 interventional study of IBI362 and Semaglutide in Type 2 Diabetes and Obesity, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-11.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
349
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 909 studies in Diabetes Mellitus, Type 2 with a site in China — 205 open to participants now, 228 under way, 46 of them phase 3. Diabetes Mellitus, Type 2 · China.

Enrollment
258th of 767
349 · median 199
Started
2024
with 82 others
Phase 3
207 of 909
38 open now
Registered
625th of 909
by date

Among the 909 studies in Diabetes Mellitus, Type 2 with a site in China, this one is the 258th largest by enrollment of the 767 interventional ones that give a count, is one of 83 that started in 2024, is one of 207 in phase 3, and was the 625th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

205 of the 909 studies in Diabetes Mellitus, Type 2 with a site in China are open now. Recruiting first, the newest first:

200 more — sign in →

All 205 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 909 studies in Diabetes Mellitus, Type 2 with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, randomized, Open-label Phase 3 clinical study comparing the efficacy and safety of IBI362 6 mg OW versus Semalgutide 1 mg OW in obese(BMI≥28kg/m2) early T2D subjects. Subjects will be randomly assigned to IBI362 6 mg and Semalgutide 1 mg groups for 32 weeks (active-controlled treatment period). In the extension period, participants originally on mazdutide were assigned to continue for an additional 24 weeks with mazdutide 9 mg or 6 mg based on whether they achieved the weight-loss target. All study treatment will be administered once-weekly and subcutaneously. The entire trial cycle includes a 2-week screening period, a 32-week active-controlled treatment period, a 24 week extension period and a 4-week drug withdrawal safety follow-up period.

03

Conditions studied

  • Type 2 Diabetes
  • Obesity
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, age 18 years or older at the time of signing
  • T2D was diagnosed according to WHO standards in 1999(≤5 years)
  • The blood glucose was not well controlled after diet and exercise with/without sable metformin(≥1500mg/day,no more than 2550mg/day) within 3 months before screening, and the local laboratory tested 7.5% ≤ ≤9.5% during screening
  • Have a ≥28 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Subjects who the investigator thinks may be allergic to the components in the study drug or similar drugs
  • A self-reported change in body weight above 5% within 3 months before screening
  • Oral hypoglycemic drugs other metformin have been used within 2 months before screening.
  • Previous diagnosis of type 1 diabetes (including adult latent diabetes)
  • There are active or untreated malignant tumors within 5 years before screening, or patients are in remission of clinical malignant tumors (except patients with skin basal cell carcinoma and squamous cell carcinoma, cervical carcinoma in situ, prostate carcinoma in situ or papillary thyroid carcinoma who have no recurrence after surgery)
  • Mental illness existed in the past or at the time of screening, and the researcher thinks it is not suitable to participate in this study
  • Pregnant or lactating women, or men or women who are fertile and unwilling to use throughout the study period
  • The investigator believes that the subject has any other factors that may affect the efficacy or safety evaluation of this study and is not suitable to participate in this study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
349 participants (actual)

Study arms

  • Active comparator
    Semaglutide

    Drug: Semaglutide

  • Experimental
    IBI362

    Drug: IBI362

Interventions

  • DrugIBI362

    Once-weekly injections of gradually increased doses of IBI362, subcutaneously (SC),starting dose is IBI362 2.0 mg, continuous After 4 weeks of administration, increase to IBI362 4.0 mg. After 4 weeks of continuous administration, continue to increase to IBI362.

  • Once-weekly injections of gradually increased doses of Semaglutide, subcutaneously (SC),starting dose is semaglutide 0.25mg, after 4 weeks of continuous administration, increase to semaglutide 0.5mg, after 4 weeks of continuous administration, continue Upgrade to semaglutide 1.0 mg for 24 weeks.

06

What researchers measure

Primary outcomes

  1. Proportion of subjects who achieve composite endpoint of HbA1c <7.0% and ≥10% weight loss

    Time frame: Week 32

Secondary outcomes

  1. Proportion of subjects who achieve composite endpoint of HbA1c <7.0% and ≥15% weight loss

    Time frame: Week 32

  2. Proportion of subjects who achieve composite endpoint of HbA1c <7.0% and ≥5% weight loss

    Time frame: Week 32

  3. Proportion of subjects who achieve composite endpoint of HbA1c<6.5% and ≥5%, ≥10% or ≥15% weight loss

    Time frame: Week 32

  4. Change from Baseline in HbA1c

    Time frame: Week 32

  5. Change in fasting plasma glucose(FPG) from baseline

    Time frame: Week 32

  6. Change in 7-point self-monitored blood glucose(SMBG) from baseline

    Time frame: Week 32

  7. Proportion of subjects achieving HbA1c < 7.0%, ≤ 6.5%, and < 5.7%

    Time frame: Week 32

  8. Change in body weight from baseline

    Time frame: Week 32

  9. Percent change in body weight from baseline

    Time frame: Week 32

  10. Change in waist circumference from baseline

    Time frame: Week 32

  11. Change in body mass index (BMI) from baseline

    Time frame: Week 32

  12. Proportion of subjects achieving weight loss of ≥ 5%, ≥ 10%, or ≥ 15%

    Time frame: Week 32

  13. Proportion of patients achieving 24 kg/m 2≤ BMI < 28 kg/m 2 and 18.5 kg/m 2≤ BMI < 24 kg/m 2

    Time frame: Week 32

  14. Change in systolic blood pressure(SBP) and diastolic blood pressure(DBP) from baseline

    Time frame: Week 32

  15. Change in lipids [total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG)] from baseline

    Time frame: Week 32

  16. Changes in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) from baseline

    Time frame: Week 32

  17. Change in serum uric acid from baseline

    Time frame: Week 32

  18. Change in quality of life (IWQoL-Lite-CT) from baseline

    Time frame: Week 32

  19. Change in quality of life (SF-36 v2) from baseline

    Time frame: Week 32

  20. Change in HOMA2-β from baseline

    Time frame: Week 32

  21. Change in HOMA2-IR from baseline

    Time frame: Week 32

07

Study locations

1 site
  • Peking University People's Hospital
    Beijing, Beijing Municipality 100010, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in Sep 2025, 18 months.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 18 months is close to that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2023
First posted
Dec 28, 2023
StartActual
Feb 29, 2024
Primary completionActual
Sep 17, 2025
CompletionActual
Feb 9, 2026
Last update
Jun 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06184568
Responsible party
Sponsor
First posted
Dec 28, 2023
Start date
Feb 29, 2024
Primary completion
Sep 17, 2025
Completion
Feb 9, 2026
Last update
Jun 11, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mazdutide

Start the discussion